Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04180176 · ClinicalTrials.gov registry record · Phase 4
Prospective Clinicogenomic Program
A Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), sponsored by Genentech.
- Completed
- Registry status
- Phase 4
- Development phase
- 945
- Enrollment target
- 20
- Study locations
NCT04180176 is a Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) that has completed, run by Genentech. The registered enrollment target is 945 participants, above the 272-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (247% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04180176, a Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 945 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Conditions Studied
Interventions
- OTHER Blood Draw
Study Locations (20)
Florida
- Florida Cancer Specialists; Department of Oncology - Fort Myers
- Florida Cancer Specialist, North Region - St. Petersburg
- SCRI Florida Cancer Specialists PAN - Tallahassee
- Florida Cancer Specialists - West Palm Beach
New York
- Hematology Oncology Associates of Central New York - East Syracuse
- West Clinic - New York
- National Translational Research Group - Port Jefferson Station
Alabama
- Alabama Oncology - Birmingham
- Clearview Cancer Institute - Huntsville
Georgia
- University Cancer & Blood Center, LLC; Research - Athens
- Piedmont Cancer Institute, PC - Atlanta
Arizona
- Ironwood Cancer & Research Centers - Chandler
Connecticut
- Yale University - New Haven
Indiana
- Fort Wayne Med Oncology & Hematology Inc - Fort Wayne
Michigan
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 945 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04180176
The ClinicalTrials.gov registry entry for NCT04180176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 945 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 272-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (247% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT04180176 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04180176 about?
NCT04180176 is a clinical study titled "Prospective Clinicogenomic Program". The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. ...
What is the current status of trial NCT04180176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 945 participants. The study started on 2019-12-13. Estimated completion is 2023-11-30.
What conditions does trial NCT04180176 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT04180176?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT04180176?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04180176 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Non-small Cell Lung Cancer (NSCLC)
All registered trials for this condition
Small Cell Lung Cancer (SCLC)
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.